Here's Shares Agios Pharmaceuticals: 2026 Outlook and Rally
Biotech investors watched Agios Pharmaceuticals spark a notable rally after key quarterly results and a strong Aqvesm...
We review 2024 tax-efficient index fund options and provide practical guidance for incorporating them into a retirement strategy.
24,809 articlesBiotech investors watched Agios Pharmaceuticals spark a notable rally after key quarterly results and a strong Aqvesm...
Shimmick's Q1 2026 results offer a window into infrastructure demand and cost pressures. This article breaks down the...
As Greg Abel steers Berkshire Hathaway's non-insurance businesses, Berkshire Hathaway Energy could emerge as a reliab...
As ATS gears up for its Q4 2026 results, investors want clarity on revenue momentum, margins, and guidance. This arti...
As Cognyte readies its Q1 2027 earnings report, investors want clarity on growth, margins, and cash flow. This guide ...
As 2026 unfolds, three robotics stocks stand out in the M&A spotlight, driven by cash flow, autonomous tech stacks, a...
Celsius has moved into the spotlight as a growth play in beverages. This article lays out five practical reasons Cels...
A major tech partnership and improving chip demand helped Intel stock climb sharply on Thursday. This deep dive expla...
Cantor Fitzgerald analyst CJ Muse contends memory supply will tighten into 2027, a view that could drive Micron's ear...
As AI workloads push data-center networks to the limit, Ciena could be uniquely positioned to turn a hidden opportuni...
Chipotle faces its first full year of negative comps while McDonald’s leads with traffic recovery and value pricing. ...
AI-driven models flag XRP as the most likely to post the biggest gains in the second half of 2026, even as Bitcoin an...